Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice

作者:Min Li Juan; Kobayashi Yodai; Mogi Masaki*; Tsukuda Kana; Yamada Akio; Yamauchi Koji; Abe Fumiaki; Iwanami Jun; Xiao Jin Zhong; Horiuchi Masatsugu
来源:PLos One, 2017, 12(2): e0171515.
DOI:10.1371/journal.pone.0171515

摘要

There is a growing interest in identifying natural food ingredients that may serve to prevent dementia such as that due to Alzheimer disease (AD). Peptides derived from food proteins have been demonstrated to have various physiological activities such as a hypotensive action. Recent findings have indicated possible associations of hypertension with AD progression, and suggest that angiotensin converting enzyme (ACE) inhibitors with potential to pass through the blood brain barrier (BBB) may reduce the risk of AD. In this study, we investigated the effect of milk peptide (CH-3) on cognitive function in AD model mice. CH-3 contains a tripeptide (methionine-lysine-proline, MKP) that has been found to have a strong ACE inhibitory effect and the potential to pass through the BBB. Adult male ddY mice were used in this study, and an animal model of AD was induced by intracerebroventricular (ICV) injection of A beta 1-42. CH-3 (250 mg/kg/day) or MKP (0.5 mg/kg/day) was orally administered every day starting 2 days before ICV injection. At 3 weeks after ICV injection, cognitive function was evaluated by the Morris water maze test. Brain samples were obtained after behavioral testing, and expression of inflammatory cytokines and NADPH oxidase subunits was measured by real-time quantitative RT-PCR. ICV injection of A beta 1-42 significantly impaired cognitive function compared with that in PBS-injected mice. Daily administration of CH-3 markedly attenuated this A beta 1-42-induced cognitive decline. A beta 1-42 injection significantly enhanced the expression of tumor necrosis factor-alpha (TNF-alpha), inducible nitric oxide synthase (iNOS) and p22(phox) in the mouse hippocampus compared with PBS injection, and showed a tendency to increase the expression of monocyte chemoattractant protein-1 (MCP-1), p47(phox) and gp91(phox), whereas CH-3 treatment markedly reduced A beta 1-42-induced TNF-alpha, MCP-1, iNOS, p47(phox) and gp91(phox) expression. Finally, administration of MKP also attenuated A beta 1-42-induced cognitive impairment with an increase in cerebral blood flow. The present study demonstrated that repeated oral administration of CH-3 to AD model mice not only improved cognitive function but also suppressed the expression of inflammatory cytokines and production of oxidative stress, and suggests its therapeutic potential for preventing cognitive impairment in AD.

  • 出版日期2017-2-3